The human voltage-gated sodium channel, hNaV1. 5, is responsible for the rapid upstroke of
the cardiac action potential and is target for antiarrhythmic therapy. Despite the clinical …

The human ether-a-go-go-related gene (hERG) not only encodes a potassium-selective
voltage-gated ion channel essential for normal electrical activity in the heart but is also a …

Although no antiarrhythmic agent has ideal pharmacokinetic and pharmacodynamic
characteristics, it is useful to evaluate antiarrhythmic agents in terms this ideal profile. The …

Amiodarone, an iodinated benzofuran derivative, introduced in 1960's as an anti-anginal
agent, emerged as a potent anti-arrhythmic agent by 1970's and is currently one of the most …

Disturbances in cardiac rhythm, also termed cardiac arrhythmias, can arise from structural
heart disease, adverse drug interactions, or inherited gene variants in ion channels or the …

The human ether-a-go-go-related gene (hERG) not only encodes a potassium-selective
voltage-gated ion channel essential for normal electrical activity in the heart but is also a …

Many different types of drugs–from antibiotics to blood pressure medication–tend to interfere
with the body's ability to control heart rhythm by disrupting the proteins in heart cells that …

Background Nifekalant, a first-line drug for the treatment of ventricular
tachycardia/ventricular fibrillation (VT/VF) in Japan, has been known to prolong the QT …

Myocardial protection with cardioplegia has resulted in significant improvement in the
outcomes of cardiopulmonary bypass (CPB) in coronary artery-bypass graft (CABG) …

Myocardial protection with cardioplegia has resulted in significant improvement in the
outcomes of cardiopulmonary bypass (CPB) in coronary artery-bypass graft (CABG) …